<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="652">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569188</url>
  </required_header>
  <id_info>
    <org_study_id>Asstmantova</org_study_id>
    <nct_id>NCT04569188</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma in COVID-19 Elderly Patients</brief_title>
  <acronym>RESCUE</acronym>
  <official_title>Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Socio Sanitaria Territoriale di Mantova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale di Mantova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trend of the spread of the COVID-19 pandemic demonstrates in Lombardy, starting from
      28.03.2020, a slowdown in the exponential phase of infections and the probable reaching of a
      plateau phase.

      However, a marked increase in infections was observed in the so-called &quot;protected structures&quot;
      such as nursing homes (RSA), both in health staff and in the residents of such facilities.
      The observed percentage of lethality, according to the more recent data provided by the
      National Institute of Health, is very high especially among residents.

      For these reasons, the city Hospital (ASST) of Mantua , already involved in the use of
      hyperimmune plasma as a therapy for COVID-19, designed this study in order to evaluate RSA
      patients and to identify the cases eligible for this treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For a detailed description of the study, see the attached protocol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">August 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>15 days</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>7 days</time_frame>
    <description>Naso-pharyngeal swab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort of elderly patients treated with convalescent plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>COVID-19 elderly patients treated with convalescent plasma</description>
    <arm_group_label>convalescent plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly patients (&gt; 65 years old) with SARS-CoV-2 RT-PCR positivity on nasal swab or
             score higher than 5 with the following characteristics:

               -  New onset or worsening of recently onset respiratory symptoms (&lt;10 days);

               -  Radiological imaging (CT, X-ray, Ultrasound) of bilateral pulmonary opacities not
                  fully explained by pleural effusion, pulmonary or lobar atelectasis, pulmonary
                  nodules;

               -  Respiratory failure (SpO2 &lt;95%) not fully explained by heart failure or water
                  overload (after excluding hydrostatic causes of edema in the absence of risk
                  factors by objective assessment, for example ultrasound);

          -  Patients who have signed informed consent.

        Exclusion Criteria:

          -  New onset or worsening of respiratory symptoms that began more than 10 days ago;

          -  Patients with proven hypersensitivity or allergic reaction to plasma, blood products
             or immunoglobulins;

          -  Manifest desire not to be included in the research protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Franchini</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Mantova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Transfusion Service</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale di Mantova</investigator_affiliation>
    <investigator_full_name>Massimo Franchini</investigator_full_name>
    <investigator_title>Director Immunohematology and Transfusion Service</investigator_title>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT04569188/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

